ArticleMicroorganisms2018
Combination of Posaconazole and Amphotericin B in the Treatment of
Article in Microorganisms, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Synergistic eradication ofFrontiers in medicine · 2026Article
- Antifungal resistance: Emerging mechanisms and implications (Review).Molecular medicine reports · 2025Review
- Shifting Paradigms in Antifungal Prophylaxis and Their Effects on Candidemia Outcomes in Hematological Malignancies: A 14-Year Experience from a Single Tertiary Center.Journal of fungi (Basel, Switzerland) · 2025Article
- Interspecies Interactions of Single- and Mixed-Species Biofilms ofBiomedicines · 2025Article
- Repurposing Mouthwashes: Antifungal and Antibiofilm Abilities of Commercially Available Mouthwashes AgainstAntibiotics (Basel, Switzerland) · 2025Article
- Article
- Azole Combinations and Multi-Targeting Drugs That Synergistically InhibitJournal of fungi (Basel, Switzerland) · 2024Review
- Are Mouthwashes Really Effective againstJournal of fungi (Basel, Switzerland) · 2024Review
- Antifungal Susceptibility andBiomedicines · 2024Article
- Enhanced antifungal activity of posaconazole against Candida auris by HIV protease inhibitors, atazanavir and saquinavir.Scientific reports · 2024Article
- Characterization of OralAntibiotics (Basel, Switzerland) · 2023Article
- Combination of Farnesol with Common Antifungal Drugs: Inhibitory Effect againstMedicina (Kaunas, Lithuania) · 2023Article
- Saprochaete clavata invasive infection: characterization, antifungal susceptibility, and biofilm evaluation of a rare yeast isolated in Brazil.Revista do Instituto de Medicina Tropical de Sao Paulo · 2023Article
- Overview on the Infections Related to RarePathogens (Basel, Switzerland) · 2022Review
- Current and promising pharmacotherapeutic options for candidiasis.Expert opinion on pharmacotherapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Candidemia cases have been increasing, especially among immunosuppressed patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.